stockrow
Friday 6 November 2026
Export PRVA’s income statement to Excel — free account
Privia Health Group, Inc.
PRVA Healthcare Health Information Services
Privia Health Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 22.3% from fiscal 2024.
- Revenue
- +13.2%
- EPS
- +83.3%
- Free cash flow
- −44.4%
Quarter to September 2026, against a year earlier
24.32
0.38
+1.59%
Follow PRVA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
6 | 6 | 7 | — |
| 3.11% | 2.87% | 3.58% | 4.25% | ||
| 1.83% | 1.67% | 2.04% | 2.38% | ||
ROIC |
6.87% | 5.89% | 6.59% | 7.47% | |
Return on Tangible Assets |
6.68% | 5.96% | 7.19% | 8.15% | |
Average Days of Receivables |
68.93 | 83.46 | 88.87 | 93.49 | |
Free Cash Flow per Share |
1.34 | 1.11 | 1.04 | 0.85 | |
Free Cash Flow |
163.40 | 138.00 | 131.13 | 108.07 | |
| Other line items | |||||
Cash ROIC |
12.86% | 11.26% | 10.49% | 8.19% | |
Accounts Receivable Turnover |
5.92 | 4.98 | 4.63 | 4.34 | |
Accounts Payable Turnover |
21.40 | 27.21 | 25.67 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | |
Average Days of Payables |
18.47 | 14.54 | 15.66 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
(0.32) | (0.39) | (0.40) | (0.37) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
7.79% | 7.85% | 7.62% | 7.29% | |
Share Based Compensation of Revenue |
3.35% | 3.35% | 3.21% | 2.91% | |
Operating CF/Net income |
7.13 | 6.34 | 4.66 | 3.11 | |
Depreciation/Fixed assets |
19.66 | 29.39 | 44.34 | 12.56 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
17.38 | 18.10 | 18.70 | 19.09 | |
Operating CF per Share |
1.34 | 1.11 | 1.04 | 0.85 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026